Guanhao Biotech Co.,Ltd.

SZSE:300238 株式レポート

時価総額：CN¥3.5b

Guanhao BiotechLtd 過去の業績

過去 基準チェック /26

Guanhao BiotechLtd has been growing earnings at an average annual rate of 32%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been declining at an average rate of 4.3% per year. Guanhao BiotechLtd's return on equity is 0.8%, and it has net margins of 4.7%.

主要情報

32.0%

収益成長率

32.0%

EPS成長率

Biotechs 業界の成長11.3%
収益成長率-4.3%
株主資本利益率0.8%
ネット・マージン4.7%
前回の決算情報30 Sep 2024

最近の業績更新

Solid Earnings May Not Tell The Whole Story For Guanhao BiotechLtd (SZSE:300238)

Nov 04
Solid Earnings May Not Tell The Whole Story For Guanhao BiotechLtd (SZSE:300238)

Recent updates

Solid Earnings May Not Tell The Whole Story For Guanhao BiotechLtd (SZSE:300238)

Nov 04
Solid Earnings May Not Tell The Whole Story For Guanhao BiotechLtd (SZSE:300238)

Subdued Growth No Barrier To Guanhao Biotech Co.,Ltd. (SZSE:300238) With Shares Advancing 38%

Oct 24
Subdued Growth No Barrier To Guanhao Biotech Co.,Ltd. (SZSE:300238) With Shares Advancing 38%

Optimistic Investors Push Guanhao Biotech Co.,Ltd. (SZSE:300238) Shares Up 28% But Growth Is Lacking

Sep 02
Optimistic Investors Push Guanhao Biotech Co.,Ltd. (SZSE:300238) Shares Up 28% But Growth Is Lacking

Guanhao Biotech Co.,Ltd. (SZSE:300238) May Have Run Too Fast Too Soon With Recent 28% Price Plummet

Jun 07
Guanhao Biotech Co.,Ltd. (SZSE:300238) May Have Run Too Fast Too Soon With Recent 28% Price Plummet

Guanhao Biotech Co.,Ltd.'s (SZSE:300238) 26% Share Price Plunge Could Signal Some Risk

Apr 23
Guanhao Biotech Co.,Ltd.'s (SZSE:300238) 26% Share Price Plunge Could Signal Some Risk

Guanhao Biotech Co.,Ltd.'s (SZSE:300238) 32% Share Price Surge Not Quite Adding Up

Mar 09
Guanhao Biotech Co.,Ltd.'s (SZSE:300238) 32% Share Price Surge Not Quite Adding Up

収支内訳

Guanhao BiotechLtd の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

SZSE:300238 収益、費用、利益 ( )CNY Millions
日付収益収益G+A経費研究開発費
30 Sep 243731822142
30 Jun 243832022540
31 Mar 243832322142
31 Dec 234043122945
30 Sep 23392-3523543
30 Jun 23385-3323046
31 Mar 23367-30721650
01 Jan 23377-30821951
30 Sep 22411-21820451
30 Jun 22429-21120552
31 Mar 224837723249
01 Jan 224897424547
30 Sep 214907026444
30 Jun 214966027436
31 Mar 214725325934
31 Dec 204374723334
30 Sep 20439-44328567
30 Jun 20434-44727069
31 Mar 20424-46427568
31 Dec 19438-46529570
30 Sep 194703524138
30 Jun 194714825640
31 Mar 194815226541
31 Dec 184584625143
30 Sep 184474725747
30 Jun 184563523771
31 Mar 184584126361
31 Dec 174614626450
30 Sep 174535026334
30 Jun 17406582590
31 Mar 17351572050
31 Dec 16313571830
30 Sep 16265631420
30 Jun 16246621320
31 Mar 16236631260
31 Dec 15226631220
30 Sep 15206531250
30 Jun 15197511220
10 Apr 15192511210
31 Dec 14190501220
30 Sep 14176441150
30 Jun 14172421150
31 Mar 14168411130
31 Dec 13169411170

質の高い収益: 300238 has a large one-off gain of CN¥6.4M impacting its last 12 months of financial results to 30th September, 2024.

利益率の向上: 300238 became profitable in the past.

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 300238 has become profitable over the past 5 years, growing earnings by 32% per year.

成長の加速: 300238 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

収益対業界: 300238 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (0.08%).

株主資本利益率

高いROE: 300238's Return on Equity (0.8%) is considered low.

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y